31 Mar 2020 14:37
31 March 2020
Cathay International Holdings Limited
("Cathay" or the "Company")
Lansen reports annual results for the year ended 31 December 2019
Hong Kong, 31 March 2020 - Cathay International Holdings Ltd. (LSE: CTI.L), an operator and investor in the growing healthcare sector in the People's Republic of China, today notes Lansen Pharmaceutical Holdings Ltd ("Lansen") (HKEX: 503), the Company's 52.83% owned subsidiary, has reported its annual results for the year ended 31 December 2019 in accordance with the requirements of its Hong Kong listing.
The full text of the Lansen Announcement can be found at https://www1.hkexnews.hk/listedco/listconews/sehk/2020/0331/2020033102226.pdf and will also be made available in the Announcements and Notices section of Lansen's website at http://holding.lansen.com.cn/en/newslist.aspx?NodeCode=10002000700050005.
As previously announced, Cathay will issue its Annual Results for the year ended 31 December 2019 on Wednesday 1 April 2020
- ENDS -
For further enquiries, please contact:
Cathay International Holdings Limited Eric Siu (Finance Director) Patrick Sung (Director and Controller)
|
Tel: +852 2828 9289 |
Consilium Strategic Communications Mary-Jane Elliott / Matthew Neal / Lindsey Neville
|
Tel: +44 (0) 203 709 5702
|
About Cathay
Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and an operator and investor in the healthcare sector in the People's Republic of China (the "PRC"). The Company and its subsidiaries (collectively the "Group") aim to leverage on investment opportunities in the growing domestic demand for high quality healthcare products in the PRC and build portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a track record of identifying investment opportunities in this area including: Lansen, a leading specialty pharmaceutical company focused on rheumatology and dermatology in the PRC; Haizi, a company engaged in the manufacture, marketing and sale of inositol and its by-product, di-calcium phosphate; Natural Dailyhealth, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.
The Group employs approximately 1,300 people across the PRC, including over 20 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a hotel investment. For more information please visit the Company's website: www.cathay-intl.com.hk.
About Lansen
Lansen, whose shares are listed on the main board of the Hong Kong Stock Exchange, is a 52.83% owned subsidiary of Cathay. Lansen is engaged in the manufacture, distribution and development of specialty prescription drugs for treatment of autoimmune disorder in rheumatology and dermatology. Lansen specialises in disease modifying anti-rheumatic drugs ("DMARDs") for treatment of rheumatoid arthritis ("RA") in the PRC. Lansen has established an extensive distribution network, covering more than 1,500 hospitals in 22 provinces in the PRC. For more information please visit the Lansen's website: http://www.lansen.com.cn/en/index.aspx.